English | Español
Press release submission | Jan 7, 2022

100% Recovery-GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients

Press release submission | Jan 6, 2022

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

Press release submission | Jan 5, 2022

NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

Press release submission | Jan 4, 2022

Depression screening improves care for patients with cancer

Press release submission | Dec 29, 2021

NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

Press release submission | Dec 29, 2021

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press release submission | Dec 29, 2021

Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in highly sensitized kidney transplant patients

Press release submission | Dec 28, 2021

Quidel’s Antigen Tests Detect the Omicron Variant

Trending
+ Pharmaceuticals
Patient Daily | Jun 18, 2025

ENT specialist on acid reflux: ‘You actually have a structural issue that may predispose you to sinusitis’
+ Pharmaceuticals
Patient Daily | Jun 16, 2025

American Consumer Institute questions hospital use of 340B Drug Pricing Program
+ Pharmaceuticals
Patient Daily | Jun 13, 2025

Data scientist: ‘340B sales growth was 115.5% higher than the growth of non-340B sales in 2023’
+ Pharmaceuticals
Patient Daily | Jun 19, 2025

Patients Come First spokesperson on 340B reform: ‘Americans deserve a system that prioritizes patients first, not pharmacy middlemen’